Corona Virus
Stay Safe, FollowGuidance
Fetching Location Data…
Vivek Kumar

Pfizer Inc, an American multinational pharmaceutical corporation, agreed to acquire a 9.9% stake for $200 million in CStone Pharmaceuticals, sending the Hong Kong-listed biopharmaceutical shares up about 40% on Wednesday.

The world’s second-largest pharmaceutical company, Pfizer is to license CStone’s late-stage oncology asset sugemalimab, CS1001, PD-L1 antibody, in mainland China. The Chinese biopharmaceutical company will receive up to $280 million in milestone payments for sugemalimab, and additional royalties. CStone and Pfizer will develop and commercialize additional late-stage oncology therapies in Greater China, the company said in the statement.

Pfizer has agreed to acquire 115.93 million CStone shares at a price of US$1.725 per share.

The Hong Kong-listed CStone Pharmaceuticals’ shares surged as high as 40% to HKD 12.98, highest since October last year, on Wednesday. On the other hand, Pfizer shares closed 0.60% lower at $36.17 on Tuesday; the stock is still down about 8% so far this year.

Pfizer stock forecast

Eleven analysts forecast the average price in 12 months at $42.66 with a high forecast of $55.00 and a low forecast of $35.00. The average price target represents a 17.94% increase from the last price of $36.17. From those 11 equity analysts, four analysts rated ‘Buy’, seven rated ‘Hold’ and none rated ‘Sell’, according to Tipranks.

Morgan Stanley target price is $42 with a high of $48 under a bull scenario and $31 under the worst-case scenario. Berenberg starts with hold rating; price target $38; Independent Research lowered their target price to $37 from $40; rating hold. Pfizer has been given a $43 target price by research analysts at Royal Bank of Canada. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on PFE. Mizuho reiterated a “buy” rating and set a $38 price target. Piper Sandler raised their price target to $24 from $18.50. UBS Group upped their target price to $39 from $37 and gave the stock a “neutral” rating. At last, JP Morgan lowered their target price to $36 from $37 and set a “neutral” rating.


Analyst views

“We project solid growth prospects, and the company’s COVID vaccine candidate offers optionality. Pfizer’s financials and dividend are set to adjust in 4Q20 when it completes the Viatris transaction. Pipeline execution will be key to investor perception, given late-decade patent expiration exposure,” said David Risinger, equity analyst at Morgan Stanley.

“Pfizer projects 2025 sales of $55.7 billion, which reflects 6%+ 5-yr CAGR ’20-’25. Pfizer has strong growth potential in both existing and pipeline products – it forecasts $8 billion in incremental sales from each in 2025. Non-risk adjusted pipeline revenue is projected to be $15 billion+ by 2025, including $6 billion from Vaccines, $3 billion from Inflammation & Immunology, $3 billion from Rare Disease, and $3 billion from Oncology; risk-adjusted revenue is $8 billion. Prevnar 20V is not included as part of 2025 vaccine pipeline sales because it will cannibalize the existing 13V,” Risinger added.

Upside and Downside Risks

Upside: COVID vaccine success, better COVID vaccine data than competitors, core business financial upside, positive pipeline developments, and encouraging strategic action, highlighted by Morgan Stanley.

Downside: COVID vaccine failure, COVID vaccine underperforms competitors, financial shortfalls, pipeline disappointments, disappointing strategic action, and negative US drug pricing developments.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.